The Major Histocompatibility Complex (MHC) class II DQ is an integral element of the immune system, playing a pivotal role in the body's defense mechanism. These molecules are primarily expressed on the surface of antigen-presenting cells, such as B cells, macrophages, and dendritic cells. Their main function is to present exogenous peptide antigens to helper T cells, facilitating the adaptive arm of the immune system. The MHC class II DQ proteins are highly polymorphic, which allows them to bind and present a wide array of antigens, ensuring a broad and effective immune response. The expression of these molecules is tightly controlled and can be upregulated in response to certain environmental cues, such as the presence of pathogens.
A variety of chemical compounds can serve as activators, stimulating the expression of MHC class II DQ proteins. These activators often initiate signaling pathways that lead to transcriptional activation of the genes encoding MHC class II DQ. For instance, compounds such as lipopolysaccharide (LPS), a component of bacterial cell walls, can trigger toll-like receptors, leading to a cascade that results in the heightened expression of MHC class II molecules. Similarly, synthetic compounds like CpG oligodeoxynucleotides, which mimic bacterial DNA, can also induce expression through interaction with intracellular toll-like receptor 9 (TLR9). Other chemicals, such as Vitamin D3 and retinoic acid, can also stimulate the expression of MHC class II DQ by binding to their respective receptors and activating specific nuclear transcription factors. These activators do not act in isolation; rather, they are part of a complex network of signals that finely tune the immune response by controlling the expression of MHC class II DQ proteins.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Lipopolysaccharide, E. coli O55:B5 | 93572-42-0 | sc-221855 sc-221855A sc-221855B sc-221855C | 10 mg 25 mg 100 mg 500 mg | $98.00 $171.00 $425.00 $1560.00 | 12 | |
LPS triggers toll-like receptor 4 (TLR4) on immune cells, leading to a cascade that culminates in the upregulation of MHC class II DQ expression. | ||||||
Cholecalciferol | 67-97-0 | sc-205630 sc-205630A sc-205630B | 1 g 5 g 10 g | $71.00 $163.00 $296.00 | 2 | |
As an immunomodulatory secosteroid, Cholecalciferol interacts with its receptor on immune cells, prompting the upsurge of MHC class II DQ molecules. | ||||||
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $66.00 $325.00 $587.00 $1018.00 | 28 | |
Retinoic acid engages with retinoic acid receptors, resulting in transcriptional changes that include the escalation of MHC class II DQ levels. | ||||||
Thalidomide | 50-35-1 | sc-201445 sc-201445A | 100 mg 500 mg | $111.00 $357.00 | 8 | |
Thalidomide engages cellular mechanisms that can lead to the enhanced transcription and subsequent expression of MHC class II DQ. | ||||||
PGE2 | 363-24-6 | sc-201225 sc-201225C sc-201225A sc-201225B | 1 mg 5 mg 10 mg 50 mg | $57.00 $159.00 $275.00 $678.00 | 37 | |
PGE2 binds to its E-prostanoid receptors on various immune cells, which can lead to the increased expression of MHC class II DQ. | ||||||
Azathioprine | 446-86-6 | sc-210853D sc-210853 sc-210853A sc-210853B sc-210853C | 500 mg 1 g 2 g 5 g 10 g | $203.00 $176.00 $349.00 $505.00 $704.00 | 1 | |
Azathioprine can lead to the oxidative stress response, which may include the increased expression of MHC class II DQ on antigen-presenting cells. | ||||||
Budesonide | 51333-22-3 | sc-202980 sc-202980A sc-202980B sc-202980C | 50 mg 100 mg 200 mg 500 mg | $79.00 $90.00 $154.00 $350.00 | 3 | |
Budesonide may exert a promoting effect on MHC class II DQ expression through its action on nuclear factor-kappa B (NF-κB) pathways. | ||||||
Methotrexate | 59-05-2 | sc-3507 sc-3507A | 100 mg 500 mg | $94.00 $213.00 | 33 | |
Methotrexate can stimulate the expression of MHC class II DQ by interfering with folate metabolism and subsequent immunological signaling. | ||||||